CancerVax Adds Key Members to Its Research Team
01 Agosto 2024 - 2:01AM
CancerVax, Inc., the developer of breakthrough cancer drugs that
will use the body’s immune system to fight cancer, today announced
that the Company has added two key members to its cancer research
team. Dr. Jonathan Lakey will serve as Chief Scientific Advisor and
Dr. Adam Grant will serve as Principal Scientist.
"We are thrilled to announce the addition of these two
distinguished scientists to the CancerVax team,” said Byron Elton,
CancerVax CEO.
“Jonathan Lakey, PhD, steps into the role of Chief Scientific
Advisor. Dr. Lakey brings extensive experience in biomedical
engineering and experimental surgery, with a notable focus on
diabetes and stem cell research. His leadership and scientific
acumen will be instrumental as we advance our mission to develop
revolutionary cancer treatments.”
“Adam Grant, PhD, joins us as Principal Scientist. Dr. Grant
graduated from Brigham Young University with a BS in bioinformatics
and obtained a PhD in cancer biology from the University of
Arizona. Dr. Grant was the inventor of a software patent that
improves neoantigen detection. This patent has been licensed to
improve CAR-T cell detection of cancer cells. During his
professional career, Dr. Grant has been heavily involved in the
immunotherapy space, striving to identify cancer patients who will
benefit from combination therapy of anti-pd-1 inhibition and Treg
reduction through CCR4 inhibition. His expertise will be invaluable
in fostering a collaborative and innovative research
environment.”
Mr. Elton concluded, “We are confident that the addition of
these two distinguished scientists will significantly enhance our
efforts to create better ways to treat cancer.”
About Us
CancerVax, Inc. is a pre-clinical biotechnology company creating
a better way to treat cancer. Working with a team of world class
cancer researchers and practicing oncologists at UCLA, we are
developing a breakthrough Universal Cancer Treatment platform that
will leverage the body’s immune system to detect, mark, and destroy
only cancer cells. We have created our first cancer drug candidate
– a single-disease specific immunotherapy targeting Ewing sarcoma,
a rare but deadly bone and soft tissue cancer primarily affecting
children and young adults. We look forward to the day when treating
cancer will be as simple as getting a shot – a better way to treat
cancer. To learn more, please visit www.CancerVax.com
Forward-Looking Statements
This press release may contain “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current beliefs,
expectations, and assumptions regarding the future of our business,
plans and strategies, projections, anticipated events and trends,
the economy, and other future conditions. Because forward-looking
statements relate to the future, they are subject to inherent
uncertainties, risks, and changes in circumstances that are
difficult to predict, many of which are outside our control. Our
actual results and financial condition may differ materially from
those in the forward-looking statements. Therefore, you should not
rely on any of these forward-looking statements. Any
forward-looking statement made by us in this release is based only
on information currently available to us and speaks only as of the
date it is made. We undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments, or otherwise.
Press Contact:CancerVax, Inc.Tel: (805)
356-1810communications@CancerVax.com